| Name | Title | Contact Details |
|---|
Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company’s products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections. It is also developing SYR-472, which is in Phase III clinical trials for the treatment of Type-2 diabetes. In addition, the company has rights to compounds in various stages of development and commercialization, which includes Nesina, Liovel, Oseni, and Kazano for the treatment of Type-2 diabetes, as well as Priligy for the treatment of premature ejaculation. The company was founded in 1998 and is headquartered in Morrisville, North Carolina.
Framework Health Plan is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Founded at MIT, the Embr Wave® & Wave 2 are personal cooling bands and heated wearables for fast, natural thermal wellness and thermotherapy.
Otsuka America is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Familymeds Group Inc is a Farmington, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.